Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.

Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC.

Cancer Sci. 2009 Mar;100(3):434-40. doi: 10.1111/j.1349-7006.2009.01076.x. Epub 2009 Jan 14.

2.

The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.

Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, Kohn EC.

Carcinogenesis. 2008 Mar;29(3):466-72. Epub 2007 Oct 4.

PMID:
17916899
3.

Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.

Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC.

Clin Cancer Res. 2010 Jan 15;16(2):600-9. doi: 10.1158/1078-0432.CCR-09-1979. Epub 2010 Jan 12.

4.

Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.

Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S, Davidson B, Kohn EC.

Gynecol Oncol. 2011 Sep;122(3):656-62. doi: 10.1016/j.ygyno.2011.04.052. Epub 2011 Jun 14.

5.

Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression.

Wex T, Kuester D, Schönberg C, Schindele D, Treiber G, Malfertheiner P.

BMC Gastroenterol. 2011 May 26;11:63. doi: 10.1186/1471-230X-11-63.

6.

Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells.

Choi BD, Jeong SJ, Wang G, Park JJ, Lim DS, Kim BH, Cho YI, Kim CS, Jeong MJ.

Int J Mol Med. 2011 Oct;28(4):527-34. doi: 10.3892/ijmm.2011.726. Epub 2011 Jun 17.

PMID:
21687932
7.

Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells.

Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie X, Tang Z, Jiang X.

Clin Transl Oncol. 2015 Apr;17(4):314-21. doi: 10.1007/s12094-014-1232-4. Epub 2014 Oct 16.

PMID:
25319722
8.

Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.

Wen J, Nikitakis NG, Chaisuparat R, Greenwell-Wild T, Gliozzi M, Jin W, Adli A, Moutsopoulos N, Wu T, Warburton G, Wahl SM.

Am J Pathol. 2011 Jun;178(6):2866-78. doi: 10.1016/j.ajpath.2011.02.017.

9.
10.

Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.

Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1730-5. doi: 10.1158/1055-9965.EPI-12-1368. Epub 2013 Jul 22.

11.

Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.

Nakamura K, Takamoto N, Hongo A, Kodama J, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y.

Oncol Rep. 2008 May;19(5):1085-91.

PMID:
18425362
12.

A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation.

Klimenkova O, Ellerbeck W, Klimiankou M, Ünalan M, Kandabarau S, Gigina A, Hussein K, Zeidler C, Welte K, Skokowa J.

Blood. 2014 Feb 20;123(8):1239-49. doi: 10.1182/blood-2013-06-508887. Epub 2013 Dec 18.

13.

Secretory Leukocyte Protease Inhibitor (SLPI) expression downregulates E-cadherin, induces β-catenin re-localisation and triggers apoptosis-related events in breast cancer cells.

Rosso M, Lapyckyj L, Amiano N, Besso MJ, Sánchez M, Chuluyan E, Vazquez-Levin MH.

Biol Cell. 2014 Sep;106(9):308-22. doi: 10.1111/boc.201300075. Epub 2014 Aug 6.

PMID:
25039920
14.

Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.

Sayers KT, Brooks AD, Sayers TJ, Chertov O.

PLoS One. 2014 Aug 11;9(8):e104223. doi: 10.1371/journal.pone.0104223. eCollection 2014.

15.

Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer.

Cheng WL, Wang CS, Huang YH, Liang Y, Lin PY, Hsueh C, Wu YC, Chen WJ, Yu CJ, Lin SR, Lin KH.

Int J Cancer. 2008 Oct 15;123(8):1787-96. doi: 10.1002/ijc.23746.

16.

Anti-tumor effect of SLPI on mammary but not colon tumor growth.

Amiano NO, Costa MJ, Reiteri RM, Payés C, Guerrieri D, Tateosian NL, Sánchez ML, Maffia PC, Diament M, Karas R, Orqueda A, Rizzo M, Alaniz L, Mazzolini G, Klein S, Sallenave JM, Chuluyan HE.

J Cell Physiol. 2013 Feb;228(2):469-75. doi: 10.1002/jcp.24153.

PMID:
22767220
17.

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A.

J Gene Med. 2003 Apr;5(4):300-10.

PMID:
12692864
18.

Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.

Zheng D, Gui B, Gray KP, Tinay I, Rafiei S, Huang Q, Sweeney CJ, Kibel AS, Jia L.

Oncogene. 2016 Sep 8;35(36):4807-15. doi: 10.1038/onc.2016.13. Epub 2016 Feb 15.

PMID:
26876202
20.

Secretory leukocyte peptidase inhibitor and lung cancer.

Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T.

Cancer Sci. 2008 May;99(5):849-55. doi: 10.1111/j.1349-7006.2008.00772.x. Review.

Supplemental Content

Support Center